Application Of Plasma Circulating DNA Combined With RASSF1A And CCDC181 Gene Methylation In The Diagnosis Of Breast Cancer

Objective: To investigate the diagnostic efficacy and clinical value of methylation levels of RAS-related region family 1A(RASSF1A)and CCDC181 genes in plasma free DNA and serum glycoconjugate antigen 153(CA153),serum glycoconjugate antigen 125(CA125),carcinoembryonic antigen(CEA)levels alone and in combination in breast cancer and benign breast diseases.Methods: Blood specimens were collected from December 2021 to June 2022 from 50 patients attending the Department of Surgical Oncology.The First Affiliated Hospital of Jiamusi University,of which 30 patients with breast cancer(stage I-III)were in the experimental group(tumor group)and 20 patients with benign breast diseases were in the control group.The levels of serum glycoantigen 153(CA153),serum glycoantigen 125(CA125),and carcinoembryonic antigen(CEA)were detected by chemiluminescence,and Cf-DNA was extracted from patients in the experimental and control groups,and high-throughput targeted methylation sequencing was performed to assess the methylation levels of RASSF1 A and CCDC181;ROC curves were used to assess the methylation levels of Cf-DNA and CA153,CA125 and CEA alone and in combination to diagnose BRC.Results: 1.The levels of CA153,CA125 and CEA in the experimental group were significantly higher than those in the control group,and the differences were statistically significant(P<0.005);2.The concentrations of Cf-DNA in the experimental and control groups mean ± standard deviation were(0.266 ±.068,0.227 ±.074),respectively,and P<0.05 was not statistically significant;3.There were significant differences in methylation levels in the promoter region of RASSF1 A,and the mean ± standard deviation of Cp G island methylation in the promoter region of RASSF1 A in the experimental group was(0.438 ± 0.165,0.018 ± 0.013),respectively,P<0.05 was statistically significant;4.There were significant differences in methylation levels in the promoter region of CCDC181,and the Cp G islands methylation in the promoter region of experimental group The median was 0.245(0.139,0.377)and in the experimental group and 0.024(0.018,0.035)in the control group,and their overall methylation levels are statistically different(Z=6.44,P=1.889E-10).Conclusions: Combined tumor marker detection can improve the early diagnosis rate of breast cancer;plasma Cf-DNA concentration did not differ significantly between breast cancer and benign breast disease groups,while RASSF1 A and CCDC181 methylation levels differed very significantly in BRC,which have good clinical application prospects,and plasma free DNARASSF1 A and CCDC181 gene methylation in The plasma free DNARASSF1 A and CCDC181 gene methylation have some potential in breast cancer diagnosis.